Immuno-Oncologists are at the forefront of a revolutionary approach to cancer treatment, focusing on harnessing the body’s immune system to recognize and destroy cancer cells. Unlike traditional therapies that directly target tumors through surgery, radiation, or chemotherapy, immuno-oncology empowers immune responses to detect abnormalities and fight back more effectively. This branch of oncology has led to breakthroughs such as immune checkpoint inhibitors, CAR T-cell therapy, and cancer vaccines. These treatments have shown remarkable success in certain cancers like melanoma, lung cancer, and some lymphomas, transforming previously grim prognoses into long-term remission for many patients. As a result, immuno-oncology is becoming a cornerstone of modern cancer therapy.
Immuno-oncologists work at the intersection of immunology and oncology, conducting both laboratory research and clinical trials to understand how tumors evade immune detection. They investigate biomarkers to predict treatment responses and personalize therapies based on genetic and immune profiles. As cancer is highly heterogeneous and adaptive, immuno-oncologists face the ongoing challenge of resistance mechanisms, but their innovations are steadily improving outcomes. The field continues to expand rapidly, offering new hope for patients with cancers that were once considered untreatable. With the integration of artificial intelligence, genomics, and combination therapies, immuno-oncologists are reshaping the future of cancer care, making it more targeted, durable, and patient-specific.
Title : A novel blood-based mRNA genomics technology for cancer diagnosis and treatment
Rajvir Dahiya, University of California San Francisco, United States
Title : tRNA-derived fragment 3′tRF-AlaAGC modulates cell chemoresistance and M2 macrophage polarization via binding to TRADD in breast cancer
Feng Yan, The Affiliated Cancer Hospital of Nanjing Medical University, China
Title : Integrating single-cell and spatial transcriptomics to uncover and elucidate GP73-mediated pro-angiogenic regulatory networks in hepatocellular carcinoma
Jiazhou Ye, Guangxi Medical University Cancer Hospital, China
Title : Unveiling the synergism of radiofrequency therapy and graphene nanocomposite in tumor cell viability assay
Paulo Cesar De Morais, Catholic University of Brasilia, Brazil
Title : Analysis of the dynamic evolution and influencing factors of nutritional risk in breast cancer patients during treatment
Jingwen Yan, Sun Yat-sen University, China
Title : Integrative multi-omics reveals metabolic–stemness coupling and novel therapeutic targets in osteosarcoma chemoresistance
Jinyan Feng, Tianjin Medical University Cancer Institute and Hospital, China